Her-2/neu, Estrogen And Progesterone Receptor Expression In Who Grade I Meningiomas

Kandemır, Nilüfer Onak; Gül, Aylin; Gün, Banu Doğan; Karadayi, Nimet; Yurdakan, Gamze; Özdamar, Şükrü Oğuz

doi:10.5174/tutfd.2009.01534.1

Cited by 4 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding of more frequent Her-2/neu overexpression in meningothelial meningioma (43% of the classic and 50% of the atypical/anaplastic meningothelial meningiomas) is in accordance with that of Loussouarn et al (2006) and Onak Kandemir et al (2010), who reported more frequent Her-2/ neu overexpression in meningiomas displaying epithelial differentiation, such as meningothelial and secretory histological subtypes. Durand et al (2008), however, have not found such an increased frequency of detection.…”

Section: Discussionsupporting

confidence: 91%

“…In the present study, HER-2 positivity was detected in 13 (34.2%) of the 38 meningioma specimens studied, which is within the wide range of 2.5 to 67.3% reported for Her-2/neu overexpression in meningiomas in the literature (Potti et al, 2004a(Potti et al, , 2004bLoussouarn et al, 2006;Durand et al, 2008;Abdelzaher et al, 2010;Onak Kandemir et al, 2010;Wang et al, 2010).…”

Section: Discussionsupporting

confidence: 82%

“…Meningiomas are one of the most common tumors of the central nervous system in adults (Onak Kandemir et al, 2010). Although the majority of these tumors are histologically benign, meningiomas have shown significant rates of recurrence, morbidity, and mortality in studies with a long-term follow-up (Ö zer et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

“…Values greater than 1%, that is, scores 1-3 were considered positive (Onak Kandemir et al, 2010). The grades were defined as follows: 0, r 1% positive cells; 1 + , 2-10% positive cell; 2 + , 11-50% positive cells; and 3 + , > 50% positive cells.…”

Section: Immuonhistochemical Studymentioning

confidence: 99%

“…The potential role of Her2/neu was suggested by the similarities between meningiomas and breast cancer. The literature, however, has shown wide discrepancies in Her2/neu positivity and prognostic role in meningiomas, with positivity reports extending through a wide range of 2.5 to 67.3% (Potti et al, 2004a;Loussouarn et al, 2006;Durand et al, 2008;Abdelzaher et al, 2010;Onak Kandemir et al, 2010;Wang et al, 2010). The literature, however, has shown wide discrepancies in Her2/neu positivity and prognostic role in meningiomas, with positivity reports extending through a wide range of 2.5 to 67.3% (Potti et al, 2004a;Loussouarn et al, 2006;Durand et al, 2008;Abdelzaher et al, 2010;Onak Kandemir et al, 2010;Wang et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic role of Her2/neu, progesterone receptor, and MIB-1 expression in meningioma

Khamis¹,

Rashwan²

2011

Egyptian Journal of Pathology

View full text Add to dashboard Cite

Background The clinical progress of meningiomas is difficult to predict, and risk stratification on the basis of histomorphology alone remains problematic. Investigators are currently researching numerous predictive and prognostic factors, aiming to facilitate the identification of patients with meningioma who should be followed more closely for evidence of recurrent tumor or may be treated more aggressively at the time of diagnosis.Aim In the current study, we aimed to investigate the relation between Her-2, progesterone receptor (PR), and ki-67 expression in meningiomas and patients' disease-free survival as well as some of the traditional histopathological factors, namely tumor grade and histological subtype.Methods Thirty-eight patients with sporadic intracranial meningiomas were included in the study. Patients were followed up for the time of first relapse or death from disease. The mean follow-up period was 49 months, with a median of 36 months. Original hematoxylin and eosin slides of the tumors were re-examined for histological type and grade. Sections from the paraffin-embedded tumor tissue were immunohistochemically stained for Her 2/neu, Ki67, and PRs. The dilution of the primary antibody was 1:250 for HER2/neu (Polyclonal Rabbit Anti-Human c-erb-B-2 Oncoprotein), 1:200 for ki-67 (MIB-1), and 1:100 for the progesterone receptor (PgR).Results Classical grade I meningiomas accounted for 82% of the studied cases, whereas the remaining 18% were atypical/anaplastic (grade II/III) meningiomas. HER-2 positivity was detected as membranous staining in 13 (34.2%) of the patients. HER-2 positivity for the atypical/ anaplastic meningioma group was (57.1%) as opposed to (29%) for the classical meningioma group. PRs were detected in 18 (47.4%) of the patients, with the classical group showing a (54.8%) positivity as opposed to (14.3%) in the atypical/anaplastic group. Overall, the MIB-1 proliferation index ranged from 0.5 to 18.6, the range was 0.5-2.2 with a mean of 1.197 for grade I meningiomas, whereas the range in the atypical/anaplastic group was 4.6-18.6, with a mean of 10.15. The rate of recurrence was 57% in the atypical/anaplastic group as compared with 23% in the classical meningiomas. On multivariate analysis, a statistically significant relation was found between diseasefree survival and the MIB-1 index and HER-2 expression; 73% of the recurrences occurred in HER-2 positive cases. Also, the mean survival time for HER-2-positive cases was shorter than those patients whose tumors were HER-2 negative (37 vs. 55 months). PR and tumor subtype showed no statistically significant relationship with survival. ConclusionThe study concludes that Her-2/neu expression and the MIB-1 proliferation index can be independent prognostic factors for meningioma patients' disease-free survival. We suggest that patients with tumors showing HER2 positivity and high MIB-1 labeling index should be followed more closely for evidence of tumor recurrence.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Immuonhistochemical Studymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic role of Her2/neu, progesterone receptor, and MIB-1 expression in meningioma

Khamis¹,

Rashwan²

2011

Egyptian Journal of Pathology

View full text Add to dashboard Cite

show abstract

Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females

et al. 2019

View full text Add to dashboard Cite

Background: The pathogenesis of meningioma in females and its association with exogenous progesterone is remained unclear. This study was aimed to examine expression of Progesterone receptor (PR) and Neurofibromatosis-2 (NF2) and assess their relationships to history of exogenous progesterone use and risk of meningioma.Methods: Our study was a case-control study that involves 115 females, 40 cases who diagnosed with orbito-cranial meningioma and 75 controls of healthy, that has been presented in previous study. The demographic characteristics, reproductive factors, and history of progesterone use were obtained in–depth face-to-face interviews. PR and NF2 mRNA were assessed by real-time quantitative polymerase chain reaction (RT-qPCR) on serum specimens.Results: The mean age of participants in cases vs. controls were 46.6 ± 6.2 vs. 46.5 ± 7.45 (P = 0.969). The expression of PR and NF2 in cases was significantly lower than in controls. The longer duration of progesterone exposure was significantly associated with lower expression of PR and NF2. Significant association between lower expression of PR (OR 11.7; 95% CI 4.17–32.9; P < 0.001 comparing the lowest quartile vs. 3 highest quartile of PR) and NF2 (OR 4.23; 95% CI 1.85–9.67; P = 0.001 comparing the 2 lowest quartiles vs. 2 highest quartiles) with increased risk of meningioma were also reported.Conclusion: In this study we showed that the longer the exposure to exogenous progesterone, the lower the expression of PR and NF2 mRNA in the serum. Low expression of PR and NF2 were associated with higher risk of meningioma, suggesting that low PR expression and inactivation of NF2 might play a key role in progesterone-associated meningioma tumorigenesis and may be potential clinical marker for females at higher risk of meningioma.

show abstract

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Carvalho

Silva-Martins

Magalhães³

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p = 0.486), but was significantly correlated with peritumoral edema (p = 0.031) and intratumoral calcifications (p = 0.018). Recurrent meningiomas were observed in 14.6% of cases. Immunostaining for each marker was: HLA-G 100%; HLA-E 95.6%; PR 62%; ER 2.1%; AR 6.5%; p53 92.6%; COX-2 100%; HER2 0%; Ki67, mean 2.61 ± 2.29%, median 2.1%. Primary and recurrent meningiomas showed no significant relation with HLA-E and hormone receptors (p > 0.05), except for Ki67, where a higher median was observed in recurrent tumors than in primary (p = 0.014). The larger the tumor, the more severe the peritumoral edema, and the greater the presence of calcifications. Ki67 appears to be a good biomarker of recurrence/regrowth in grade I meningiomas.

show abstract

Her-2/neu, Estrogen And Progesterone Receptor Expression In Who Grade I Meningiomas

Cited by 4 publications

References 15 publications

Prognostic role of Her2/neu, progesterone receptor, and MIB-1 expression in meningioma

Prognostic role of Her2/neu, progesterone receptor, and MIB-1 expression in meningioma

Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females

Recurrence/Regrowth in Grade I Meningioma: How to Predict?

Contact Info

Product

Resources

About